Illumina (ILMN) Target Lifted to $122 at UBS on Next-Gen Sequencing Opportunity in Clinical Oncology
Tweet Send to a Friend
UBS analyst Daniel Arias reiterated a Buy rating and raised his price target on Illumina (NASDAQ: ILMN) from $95 to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
